Pleurisy
diseaseOn this page
Also known as inflammation of pleurapleura inflammationpleuritis
Summary
Pleurisy (MONDO:0000986) is a disease with 2 GWAS associations across 10 studies and 6 clinical trials. Top therapeutic interventions include cefazolin and sodium chloride. A subtype of pleural disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 2
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pleurisy |
| Mondo ID | MONDO:0000986 |
| EFO | EFO:1001825 |
| MeSH | D010998 |
| DOID | DOID:10247 |
| ICD-10-CM | R09.1 |
| ICD-11 | 317852053 |
| NCIT | C26860 |
| SNOMED CT | 196075003 |
| UMLS | C0032231 |
| MedGen | 10807 |
| Is cancer (heuristic) | no |
Also known as: inflammation of pleura · pleura inflammation · pleuritis
Data availability: 2 GWAS associations (10 studies) · 1 cell line.
Disease family
This is a subtype of pleural disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › pleural disorder › pleurisy
Related subtypes (4): pneumothorax, congenital chylothorax, pleural empyema, pleural neoplasm
Subtypes (2): pleuropneumonia, pleural tuberculosis
Genetics & variants
GWAS landscape
2 GWAS associations across 10 studies. Top hits map to 2 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs113993960 | 1e-12 | CFTR | ? | 1.63 |
| rs140176745 | 3e-07 | NR3C1 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90018899 | Sakaue S | 2021 | 8,528 | 475,987 | A cross-population atlas of genetic associations for 220 human phenotypes. |
| GCST90652087 | Liu TY | 2025 | 2,299 | 224,406 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90077683 | Backman JD | 2021 | 1,711 | 330,043 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90081669 | Backman JD | 2021 | 1,711 | 330,043 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90077684 | Backman JD | 2021 | 1,542 | 327,510 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90081670 | Backman JD | 2021 | 1,542 | 327,510 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90080780 | Backman JD | 2021 | 798 | 385,742 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90084766 | Backman JD | 2021 | 798 | 385,742 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90018679 | Sakaue S | 2021 | 541 | 176,974 | A cross-population atlas of genetic associations for 220 human phenotypes. |
| GCST90837497 | Koyama S | 2025 | 0 | 0 | Genetics and context for precision health in Greater Boston. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 1 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| inframe_insertion | 1 |
| intron_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs113993960 | 7 | 117559591 | ATCT>A,ATCTTCT | 0.05 | inframe_insertion | CFTR | 1e-12 | Tier 1: coding |
| rs140176745 | 5 | 143389416 | G>C | intron_variant | NR3C1 | 3e-07 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE4 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02446782 | PHASE4 | COMPLETED | Efficacy and Safety of Prophylactic Use of an Antibiotic for Medical Thoracoscopy |
| NCT06525272 | PHASE1 | NOT_YET_RECRUITING | A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy |
| NCT01011881 | Not specified | COMPLETED | Procalcitonin in Pleural Pleuritis |
| NCT02107001 | Not specified | COMPLETED | Lung Ultrasound in Pleuritic Chest Pain |
| NCT02288065 | Not specified | COMPLETED | Predictive Factors and Outcome in Medical Thoracoscopy |
| NCT02500277 | Not specified | COMPLETED | Yield of Cryoprobe vs Flexible Forceps Pleural Biopsy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CEFAZOLIN | 4 | 1 |
| SODIUM CHLORIDE | 4 | 1 |
Related Atlas pages
- Drugs: Cefazolin, Sodium Chloride